TABLE 1.

Antepartum and postpartum pharmacokinetic parameters (arithmetic mean ± S.D.) of NFV in M. nemestrina after oral administration of the drug (NFV mesylate, 100 mg/kg)

Parameter Unit	AP (n = 3)	PP (n = 4)	Geometric mean ratio (AP/PP, 95% CI)
Cmax/dose (ng/ml/mg)	1.32 ± 0.39	4.36 ± 2.23	0.32 (0.17–0.61)*
Tmax (h)	2.95 ± 2.55	1.77 ± 0.51	1.34 (0.46–3.90)
AUC0-∞/dose (h · ng/ml/mg)	5.90 ± 0.75	21.0 ± 12.4	0.32 (0.18–0.60)*
CL/F (liter/h)	171 ± 23.0	61.5 ± 33.5	3.14 (1.73–5.70)*
CL/F (liter/h/kg)	21.4 ± 0.57	9.04 ± 5.22	2.73 (1.47–5.10)*
CL/Funbound (liter/h)	14,589 ± 3054	5393 ± 3325	3.04 (1.67–5.51)*
CL/Funbound (liter/h/kg)	1817 ± 190	791 ± 503	2.65 (1.43–4.88)
t1/2 (h)	3.43 ± 0.88	3.05 ± 1.12	1.17 (0.72–1.90)
F (%)	10.5 ± 0.89	19.0 ± 8.51	0.60 (0.38–0.94)*
fu (%)	1.19 ± 0.09	1.18 ± 0.30	1.03 (0.79–1.35)

C_max/dose, dose-normalized maximum plasma concentration; T_max, time to reach maximum plasma concentration; CL/F, total oral plasma clearance; CL/F_unbound, unbound oral plasma clearance; t_1/2, terminal plasma half-life; F, bioavailability; f_u, unbound in plasma

^*Significantly different antepartum versus postpartum